Monalizumab - Innate Pharma

Drug Profile

Monalizumab - Innate Pharma

Alternative Names: Anti-NKG2A; IPH-2201; IPH-22XX; NN-8765; NNC 0141-0000-0100

Latest Information Update: 05 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innate Pharma; Novo Nordisk
  • Developer Innate Pharma; MedImmune; NCIC Clinical Trials Group; Novo Nordisk
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action NK cell lectin-like receptor subfamily C antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Head and neck cancer
  • Phase I/II Cervical cancer; Chronic lymphocytic leukaemia; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase I Haematological malignancies; Solid tumours
  • Discontinued Inflammation; Rheumatoid arthritis

Most Recent Events

  • 04 Jun 2018 Updated efficacy and adverse events data from a phase I trial in Solid tumours released by Innate Pharma
  • 17 May 2018 Preliminary efficacy data from a phase I trial in Solid tumours (Combination therapy with monalizumab) released by Innate Pharma
  • 21 Apr 2018 Pharmacodynamics data from a preclinical trial in Cancer were presented at the American Association for Cancer Research (AACR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top